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Abstract
Objective: Amyotrophic lateral sclerosis (ALS) and myasthenia gravis (MG) are
caused, respectively, by motor neuron degeneration and neuromuscular junc-
tion (NMJ) dysfunction. The membrane protein LRP4 is crucial in the develop-
ment and function of motor neurons and NMJs and LRP4 autoantibodies have
been recently detected in some MG patients. Because of the critical role
in motor neuron function we searched for LRP4 antibodies in ALS patients.
Methods: We developed a cell-based assay and a radioimmunoassay and with
these we studied the sera from 104 ALS patients. Results: LRP4 autoantibodies
were detected in sera from 24/104 (23.4%) ALS patients from Greece (12/51)
and Italy (12/53), but only in 5/138 (3.6%) sera from patients with other neu-
rological diseases and 0/40 sera from healthy controls. The presence of LRP4
autoantibodies in five of six tested patients was persistent for at least
10 months. Cerebrospinal fluid samples from six of seven tested LRP4 anti-
body-seropositive ALS patients were also positive. No autoantibodies to other
MG autoantigens (AChR and MuSK) were detected in ALS patients. No differ-
ences in clinical pattern were seen between ALS patients with or without LRP4
antibodies. Conclusions: We infer that LRP4 autoantibodies are involved in
patients with neurological manifestations affecting LRP4-containing tissues and
are found more frequently in ALS patients than MG patients. LRP4 antibodies
may have a direct pathogenic activity in ALS by participating in the denervation
process.
Introduction
Amyotrophic lateral sclerosis (ALS), a heterogeneous neu-
rodegenerative disease affecting motor neurons of the
motor cortex and spinal anterior horn, has a mean survival
of 3–5 years1 and exists as a sporadic and a familial form.
The pathogenesis of sporadic ALS (~90% of all ALS cases)
remains largely obscure, explaining the absence of effective
treatments. ALS can be viewed as a “phenotypic tank” in
which groups of pathogenically heterogeneous patients
coexist while activation of the immune system during the
neurodegeneration process has been observed.2–5 Identify-
ing specific biomarkers might allow subgrouping of ALS
patients, early diagnosis, and effective intervention.6
In ALS, upper motor neuron dysfunction causes spastic-
ity, whereas lower motor neuron dysfunction leads to mus-
cle wasting, weakness, and fasciculation. Electromyographic
(EMG) changes are strongly supportive for ALS diagnosis.7
Although suggested long ago,8 the extent of neuromuscular
junction (NMJ) dysfunction in ALS is not known.
LRP4 is located at the postsynaptic membrane of the
NMJ9 and on motor neurons in the brain10 and spinal
cord.11 Upon binding to agrin, muscle LRP4 induces acti-
vation of MuSK, resulting in acetylcholine receptor
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(AChR) clustering, necessary for proper NMJ function.9
Recent data have shown that LRP4 expression in both
motor neurons and muscle is critical for the presynaptic
differentiation and survival of motor neuronal axons.11,12
Due to the critical function of LRP4, anti-LRP4
autoantibodies could cause NMJ-related diseases. Myas-
thenia gravis (MG), mainly characterized by autoantibod-
ies to AChR or MuSK,13 has recently been associated
also with LRP4 autoantibodies.14–16 LRP4 autoantibodies
inhibit agrin-mediated AChR cluster formation and are
probably pathogenic in these patients. They could also
play a role in ALS pathogenesis by inhibiting the binding
of muscle LRP4 to proteins on motor axons and inhibit-
ing the presynaptic differentiation of the motor axons,12
leading to premature withdrawal of motor nerve termi-
nals, an early step in ALS.17 In addition, animal LRP4
antibodies have been shown to reduce viability of neurons
in cell culture and to impair synaptic structure.18
We detected a high and persistent frequency of LRP4
autoantibodies in the sera and cerebrospinal fluid (CSF)
of two cohorts of ALS patients suggesting these antibodies
may play a role in the pathogenic process underlying
muscle denervation.
Material and Methods
Patients and collection of serum and CSF
samples
Serum and CSF samples were collected from two inde-
pendent cohorts of sporadic ALS patients followed by
the University Departments of Neurology in Athens (51
sera and 14 CSF) and Milan (53 sera and 10 CSF).
Overall, 164 control sera and 54 control CSFs were also
used (see Results). Samples were collected and used after
approval by the internal Review Boards of the involved
institutions and with written informed consent from
patients or relatives. The diagnosis of ALS was based on
the revised El Escorial criteria1 while other diseases were
excluded.
Assays for the detection of LRP4, AChR and
MuSK autoantibodies
LRP4 autoantibodies were detected blindly by a cell-based
assay (CBA) involving immunofluorescence with HEK293
cells transfected with human LRP4 fused to green fluores-
cent protein (GFP), using enhanced green fluorescent
protein (EGFP) transfected cells as negative controls
(modified from Pevzner et al.15; see Supplementary Meth-
ods). Anti-LRP4 antibodies were also tested by a radio-
immunoprecipitation assay (RIPA) with a polypeptide
fragment of LRP4 (amino acids 21–737; see Supplemen-
tary Methods). AChR and MuSK autoantibodies were
detected by the classical radioimmunoassays for these
antibodies (Supplementary Methods) whereas antibodies
to AChR clusters were detected by a CBA with HEK293
cells transfected with human muscle AChR subunits and
rapsin as described by Leite et al.19
Results
LRP4 antibodies in sera from ALS patients
Sera from 104 Greek and Italian sporadic ALS patients
and 164 controls were screened (at 1/100 dilution) for
LRP4 antibodies using a CBA with human LRP4 (Fig. 1).
LRP4 antibodies were detected in 23.1% of the ALS sera
(23.5% of the Greek patients and 22.6% of the Italian
patients; Table 1). Similarly, all sera were tested for bind-
ing to the N-terminal polypeptide fragment of LRP4
(amino acids 21–737; 42% of the extracellular domain of
LRP4) by a RIPA. Eight of the 24 CBA-positive sera were
found also positive by the RIPA; In addition four sera
found “ambiguous” by the CBA assay (but declared as
CBA-negative) were RIPA-positive (Fig. S1).
Sera from 6 LRP4-ALS patients were also collected
~10 months later (Fig. S2); one was found negative (with
stable clinical condition), in two the antibody titer was
doubled (both with marked worsening of their clinical con-
dition), whereas in three the antibody titer remained stable
(with marginal worsening of their clinical condition).
We then compared the anti-LRP4 titers between anti-
LRP4 positive ALS and MG sera. Serial dilutions of 21/24
LRP4-positive ALS sera were compared with those of 11
randomly chosen positive MG sera. We found that both
ALS and MG groups contained low and high titer sera
(Fig. 2) In fact, the average titer of the ALS sera (end-
point dilutions 1/895 + 563) was considerably higher than
that of the MG sera (1/632 + 361). Yet, we could not
notice any correlation between disease severity and serum
titer.
LRP4 antibodies were not detected in sera from 40
healthy individuals, four patients with familiar ALS, and
10 patients with other neurological diseases (OND), and
were detected in only 4/84 (4.8%) multiple sclerosis (MS)
patients and 1/40 (2.5%) AChR antibody-positive MG
patients. None of the tested ALS sera had detectable anti-
bodies to AChR, AChR clusters or MuSK (Table 1).
LRP4 antibodies in the CSF of seropositive
ALS patients
CSF samples from 68 ALS, MS, and OND patients were
then analysed for LRP4 antibodies. CSF samples from 6/7
tested LRP4-ALS patients and one LRP4-seropositive MS
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Figure 1. Detection of LRP4 antibodies in sera of ALS patients using a cell-based assay (CBA). Immunofluorescence study of the binding of
antibodies to HEK293 cells transfected with pCMV6-LRP4-tGFP or pEGFP. Left column: GFP fluorescence; middle column: bound antibody
staining; right column: merged images Rows 1 and 2: Commercial rabbit LRP4 antibody (1:750 dilution) was incubated with pEGFP-transfected
cells (row 1; A–C) or pCMV6-LRP4-tGFP-transfected cells (row 2; D–F) and bound antibodies visualized using Alexa 568-conjugated anti-rabbit IgG
antibodies. Rows 3–5: LRP4-GFP-transfected cells were incubated with a 1:100 dilution of serum from two ALS patients (rows 3–4; G–L) or a
healthy control (row 5, M–O) and bound antibodies visualized with Alexa 568-conjugated anti-human IgG antibodies. Only the commercial
antibody and patients’ sera bound on expressed LRP4 as visualized with red staining (E, H, K) and the merged images (F, I, L).
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patient were anti-LRP4-positive, while none of the 60
CSF from the LRP4-seronegative patients was positive
(Table 1). Comparison of serum and CSF from the same
patient at the same IgG concentration (performed for
three patients) showed that a roughly similar amount of
IgG was required for a positive LRP4 antibody result
(Fig. S3).
IgG subclass characterization of ALS
anti-LRP4 antibodies
We then examined the IgG subclass of the LRP4 antibod-
ies in sera from 17 LRP4-ALS and 13 LRP4-MG patients
(Table S1). All contained LRP4 antibodies of the predom-
inant complement activating IgG1 subclass. However,
Table 1. Detection of autoantibodies to LRP4 and other NMJ antigens in the serum and CSF from ALS patients and controls1
Patients No of samples Anti-LRP4 Anti-AChR Anti-AChR clusters Anti-MuSK
Greek sporadic ALS 51 12 (23.5%) 0 0 0
Italian sporadic ALS 53 12 (22.6%) 0 0 02
Familial ALS 4 0 0 0 0
MG (anti-AChR positive) 40 1 (2.5%) 40 22/22 0
MS 84 4 (4.8%) NT NT NT
OND 10 0 NT NT NT
Healthy controls 40 0 NT NT NT
CSF from anti-LRP4 positive ALS patients 7 6 NT NT NT
CSF from anti-LRP4 negative ALS patients 17 0 NT NT NT
CSF from patients with MS or OND 44 13 (2.3%) NT NT NT
MG, myasthenia gravis; MS, multiple sclerosis; OND, other neurological diseases.
1Serum samples from patients in two ALS cohorts (Greek and Italian) and patients with familial ALS, MG (myasthenia gravis) with AChR antibod-
ies, MS, and other neurological disease (OND) and healthy controls were tested in the cell-based assay at a 1/100 dilution for the presence of
LRP4 or AChR cluster antibodies and in the radioimmunoprecipitation assay for the presence of AChR and MuSK antibodies. CSF samples from
patients with ALS, MS, and OND were also tested, undiluted, for the presence of LRP4 antibodies.
2Two sera were found ambiguous for MuSK antibodies (titer 0.02 nmol/L). Both were LRP4-negative.
3This patient was one of the four LRP4-seropositive MS patients.
Figure 2. Comparison of the anti-LRP4 titers between ALS and MG anti-LRP4 positive sera. Twenty-one out of the 24 positive ALS sera
were tested and compared with 11 randomly chosen LRP4-positive MG sera. Sera were tested by the CBA at dilutions 1/100, 1/200, 1/400,
1/500, 1/1000, 1/2000 and 1/4000. Ambiguous result in a certain dilution is presented as an intermediate titer (e.g., ambiguous result at 1/2000
is presented as titer 1/1500)
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whereas most (11/13, 85%) LRP4-MG sera also contained
IgG2 anti-LRP4 antibodies, only 4/17 (24%) ALS sera
contained IgG2 anti-LRP4 antibodies used. Fifty percent
of the LRP4-ALS and LRP4-MG sera contained IgG3
autoantibodies, while none contained detectable IgG4
autoantibodies (Table S1).
Clinical features of ALS patients positive or
negative for LRP4 antibodies
We then compared the characteristics of the anti-LRP4-
positive and anti-LRP4-negative ALS patients in each
cohort (Table 2). In both cohorts, LRP4 antibodies were
detected both in the predominant upper and lower motor
neuron disease variants; no significant differences in terms
of clinical presentation were observed between the anti-
LRP4-positive and anti-LRP4-negative groups. In the
Greek cohort, LRP4 antibodies were more common in
patients with a bulbar onset than in those with a spinal
onset. In both cohorts, there were no significant differ-
ences between anti-LRP4-positive and anti-LRP4-negative
patients in any other tested parameter.
Discussion
LRP4 antibodies are present in some MG patients and
have been shown to inhibit AChR clustering in cell cul-
ture,14,16 strongly suggesting they may play a pathogenic
role in LRP4-MG. Interestingly, we found that LRP4 au-
toantibodies were also present in 23.1% of sera from ALS
patients and in 6/7 CSF samples from LRP4 antibody-
seropositive ALS patients; in contrast, no antibodies to
AChR, AChR clusters or MuSK were detected. Further-
more, LRP4 antibodies were present in 5/6 patients for
~10 months after their first detection. Interestingly,
changes in their autoantibody titer roughly correlated
with changes in their clinical condition (stable condition
upon decrease in antibody titer, considerable worsening
upon increase in antibody titer). This interesting indica-
tion needs further evaluation in a larger LRP4-ALS popu-
lation. The ratio of LRP4 antibodies to total IgG was
roughly similar in the serum and CSF, suggesting that
LRP4 antibodies are transported into the CSF through the
blood-brain barrier, although a parallel moderate intra-
thecal LRP4 antibody production is not unlikely. LRP4
autoantibodies were almost absent in patients with MS,
OND, and familial ALS.
The titers of LRP4 antibodies in ALS patient sera varied
considerably between patients and were comparable with
those of the MG patients and somewhat higher than their
titer values (about 50% higher) (Fig. 2). As the titers
overlapped between the two diseases, we conclude that
the anti-LRP4 titer does not determine the clinical out-
come of the disease. Interestingly, on the basis of the inci-
dence of ALS (~1/100,000) and anti-AChR/anti-MuSK
seronegative MG (~1/300,000), we calculated that the
incidence of LRP4-ALS may be three to four times higher
than that of LRP4-MG. Yet, the LRP4-ALS patients did
not cluster into any specific phenotype (Table 2).
We compared the IgG subclasses of LRP4 antibodies in
ALS and MG patients. In contrast to MuSK antibodies,
which are of the non-complement binding IgG4 subclass,
we did not detect IgG4 LRP4 autoantibodies whereas all
LRP4-ALS sera contained mostly IgG1 LRP4 autoantibod-
ies (Table S1). Interestingly, IgG2 LRP4 antibodies were
found in 85% of the LRP4-MG sera, but only in 24% of
LRP4-ALS sera. IgG1 antibodies can activate complement
much more efficiently than IgG2 and this might be of
pathogenic significance; in fact, recent data support a sig-
nificant role of complement in ALS.2,4
Although LRP4-MG is much more frequent in women
(F/M ratio ~3/1; Zisimopoulou et al., unpubl. obs.), the
gender ratio in the ALS-LRP4 patients was ~1.00. This
difference between LRP4-MG and LRP4-ALS, as well as
the difference between the two groups in the occurrence
of IgG2 autoantibodies, suggests different immune mech-
anisms for the production of LRP4 antibodies that could
result in the production of antibodies with different func-
tional characteristics, possibly responsible for the very dif-
ferent pathologies.
The identification of anti-LRP4 autoantibodies in sev-
eral ALS patients offers a potentially useful biomarker for
diagnostic purposes, but much work is needed to investi-
gate the pathogenic potential of these antibodies. Shen
et al.20 have very recently shown that mice and rabbits
immunized with LRP4 exhibit MG symptoms. Elaborate
animal studies are needed by active immunization with
LRP4 and LRP4 fragments and by passive transfer of
antibodies from immunized animals, MG and ALS LRP4-
patients, injected both in the body and in the brain of
the animals. Such kind of studies should prove the ALS-
pathogenic potential of the LRP4 antibodies, if any, and
identify any functional differences between MG and ALS
LRP4-antibodies. The earliest changes in motor neurons
of ALS patients seem to be at the nerve terminal ends.21
This may justify a possible pathogenic role of the anti-
LRP4 antibodies, at least during the first few steps of ALS
induction. Nevertheless, even if LRP4-antibodies play a
pathogenic role in ALS, clearly they are not necessary for
ALS induction in the majority of patients, as 77% of our
ALS patients did not have detectable anti-LRP4 antibod-
ies. This is not surprising as many studies have shown
that ALS is an heterogeneous spectrum of diseases rather
than a single disease with a single etiology.1
As LRP4 antibodies were also detected in the CSF
(Table 2), they might have an effect on both neuronal
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and muscle LRP4. Since animal LRP4 antibodies reduce
the neuronal viability in cell culture,18 LRP4 autoantibod-
ies with access to motor neurons could potentially cause
motor neuron degeneration.
Although an autoimmune component in ALS has been
suggested for many years,22–24 a critical role of autoim-
munity in ALS is not widely accepted, partially due to the
absence of a convincing effect of immunotherapy.25–27
Nevertheless, the timing of immunotherapy may be a crit-
ical issue in this context, as it is generally applied at
advanced stages of ALS when tissue damage has become
irreversible. In addition, a potential biomarker such as
anti-LRP4, may help to identify a group of ALS patients
in which immunotherapies may be applicable.
In conclusion, we have shown that LRP4 antibodies are
not only present in MG patients and may be more
broadly related to damage to LRP4 expressing tissues,
such as motor neurons and the NMJ. Although their
pathogenic role is still hypothetical, a direct involvement
of the immune system in the neurodegenerative process
of denervation in ALS may be envisaged due to the criti-
cal role of LRP4 in both NMJ and motor neurons, open-
ing up new therapeutic approaches. Yet, even if LRP4
autoantibodies are simply secondary to unknown patho-
genic mechanisms, they might serve as useful biomarkers
for a subgroup of ALS patients.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Supplementary Methods.
Figure S1. Measurement of anti-LRP4 antibodies in the
sera of ALS patients and healthy controls (HC) by RIPA.
LRP4 fragment, (amino acids 21–737; 42% of the LRP4
extracellular domain) was 125I-labeled and used in the
RIPA. The two horizontal lines at about 2500 and
3000 cpm denote the cutoff values for ambiguous (aver-
age of controls plus 3SD) and positive (average of con-
trols plus 4SD) result, respectively.
Figure S2. Persistence of LRP4 autoantibodies in the sera
of LRP4-ALS patients. Sera from 6 LRP4-ALS patients
were collected ~10 months after the initial test. Original
(first) and new (second) sera were then tested simulta-
neously at various dilutions (1/100–1/1600). The symbols
show the maximum dilution of each serum found posi-
tive for LRP4 antibodies. Each line represents one patient
and joins the titer of the first and second serum. It is
shown that one patient became negative, in two the anti-
body titer was doubled, whereas in three the antibody
titer remained stable.
Figure S3. Comparison of the LRP4 antibody content of
serum and CSF from the same seropositive ALS patient.
The serum and CSF samples from three LRP4 antibody-
positive ALS patients were tested at similar IgG concen-
trations in the CBA for LRP4 antibodies. For patients 1
and 2 (and in another two patients tested), serum and
CSF IgG were of roughly similar potency; in patient 3,
CSF IgG were about five times less potent than serum
IgG.
Table S1. IgG subclass characteristics of LRP4 antibodies
from ALS and MG patients.
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